Lotte Biologics secures CDMO contract with Japan-based global pharmaceutical firm for anticancer drug development and production, aiming to strengthen its competitive position in global biopharmaceutical markets including Japan through enhanced collaborative partnerships.
#YonhapInfomax #LotteBiologics #CDMO #AnticancerDrug #GlobalPharmaceutical #BiopharmaceuticalDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=113881
Lotte Biologics Signs CDMO Deal with Japan-Based Global Pharma for Cancer Drug
Lotte Biologics secures CDMO contract with Japan-based global pharmaceutical firm for anticancer drug development and production, aiming to strengthen its competitive position in global biopharmaceutical markets including Japan through enhanced collaborative partnerships.
Lotte Corp. returns to the public bond market after a two-year hiatus, aiming to shift from short-term CP to longer-term debt amid lingering concerns over petrochemical weakness and capital needs for Lotte Biologics.
#YonhapInfomax #LotteCorp #CorporateBond #CreditRating #CommercialPaper #LotteBiologics #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=106419
Lotte Corp. Returns to Public Bond Market After Two Years—Testing Move to Reduce CP Reliance
Lotte Corp. returns to the public bond market after a two-year hiatus, aiming to shift from short-term CP to longer-term debt amid lingering concerns over petrochemical weakness and capital needs for Lotte Biologics.
Lotte Biologics Co. has secured a contract manufacturing deal with Rakuten Medical Inc. for a head and neck cancer drug, aiming to expand its global CMO presence and build a supply chain from clinical trials to commercialization.
#YonhapInfomax #LotteBiologics #RakutenMedical #ContractManufacturing #HeadAndNeckCancer #SyracuseBioCampus #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=99683
Lotte Biologics Secures Contract Manufacturing Deal for Head and Neck Cancer Drug—Aims to Sustain Order Momentum
Lotte Biologics Co. has secured a contract manufacturing deal with Rakuten Medical Inc. for a head and neck cancer drug, aiming to expand its global CMO presence and build a supply chain from clinical trials to commercialization.
SK, Lotte, and Celltrion Heirs Attend JP Morgan Healthcare Conference to Secure Business Momentum
Heirs of SK, Lotte, and Celltrion attended the JP Morgan Healthcare Conference, seeking global partnerships and unveiling strategies to drive growth in the bio sector.
Lotte Hotel to Invest in Lotte Biologics Stake—Holding Company Signals Further Support
Lotte Hotel Co. will invest 214.4 billion won ($164 million) for a 19.07% stake in Lotte Biologics, as Lotte Group ramps up support for its biopharma business through new funding initiatives.
Lotte Biologics, backed by Lotte Group and led by Shin Yu-yeol, launches a 277.1 billion won rights offering to fund its Songdo plant, aiming to boost its CDMO presence amid ongoing challenges in contract acquisition and track record building.
#YonhapInfomax #LotteBiologics #RightsOffering #SongdoPlant #CDMO #ShinYuYeol #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=95097
Shin Yu-yeol-Led Lotte Biologics Secures Additional Funding for First Plant via Rights Offering—Will Its Presence Grow?
Lotte Biologics, backed by Lotte Group and led by Shin Yu-yeol, launches a 277.1 billion won rights offering to fund its Songdo plant, aiming to boost its CDMO presence amid ongoing challenges in contract acquisition and track record building.
Lotte Biologics to Raise 277.2 Billion Won in Rights Offering—Entire Proceeds Allocated to Songdo Plant 1 Construction
Lotte Biologics Co. will raise 277.2 billion won ($210 million) via a rights offering, with all proceeds dedicated to constructing its first plant at the Incheon Songdo Bio Campus.
Lotte Biologics and SK Pharmteco have signed a strategic LOI to jointly provide ADC-specialized CDMO services, aiming to expand their presence in the global antibody-drug conjugate market.
#YonhapInfomax #LotteBiologics #SKPharmteco #ADC #CDMO #GlobalMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=88171
Lotte Biologics Signs Strategic LOI with SK Pharmteco to Target Global ADC Market
Lotte Biologics and SK Pharmteco have signed a strategic LOI to jointly provide ADC-specialized CDMO services, aiming to expand their presence in the global antibody-drug conjugate market.
Lotte Biologics to Attend CPHI in Germany—Aims to Expand Global CDMO Market Presence
Lotte Biologics will participate in CPHI Worldwide in Frankfurt, showcasing its ADC manufacturing capabilities and global CDMO strategy to expand its international presence.
Lotte Biologics CEO James Park announced at BioJapan that the company aims to establish long-term partnerships with over 10 Japanese pharmaceutical firms, leveraging the Lotte brand and expanding its ADC CDMO business, while considering further investment in its U.S. Syracuse facility.
#YonhapInfomax #LotteBiologics #JamesPark #BioJapan #ADC #CDMO #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=84991
James Park, CEO of Lotte Biologics – Aims to Establish Long-Term Partnerships with Japanese Pharmaceutical Companies
Lotte Biologics CEO James Park announced at BioJapan that the company aims to establish long-term partnerships with over 10 Japanese pharmaceutical firms, leveraging the Lotte brand and expanding its ADC CDMO business, while considering further investment in its U.S. Syracuse facility.
Yonhap Infomax News